Reprogramming the Genome: CRISPR-Cas-based Human Disease Therapy

Reprogramming the Genome: CRISPR-Cas-based Human Disease Therapy

1st Edition - June 12, 2021

Write a review

  • Editor: Vijai Singh
  • eBook ISBN: 9780323853248
  • Hardcover ISBN: 9780323853231

Purchase options

Purchase options
DRM-free (EPub, Mobi, PDF)
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order


Reprogramming the Genome: CRISPR-Cas-based Human Disease Therapy, presents the collation of chapters written by eminent scientists worldwide. CRISPR-Cas9 is a key technology for targeted genome editing and regulation in a number of organisms including mammalian cells. It is a rapid, simple, and cost-effective solution. CRISPR-Cas system has recently gained much scientific and public attention. This volume covers CRISPR-Cas9 based mammalian genome editing, creating disease models, cancer therapy, neurological, heredity, blood disorders, defective gene correction, stem cells therapy, epigenetic modifications, patents, ethics, biosafety and regulatory issues challenges and opportunities. This book is a key source of information on mammalian genome editing available in a single volume. This book will be useful for beginners in mammalian genome editing and also students, researchers, scientists, policymakers, clinicians and stakeholders interested in genome editing in several areas.

Key Features

  • Offers basic understanding and a clear picture of mammalian genome editing through CRISPR-Cas systems
  • Discusses how to create mammalian disease models, stem cell modification, epigenetic modifications, correction of defective gene in blood disorders, heredity, neurological disorders and many more
  • Discusses the application of CRISPR-Cas9 systems in basic sciences, biomedicine, molecular biology, translational sciences, neurobiology, neurology, cancer, stem cells, and many more


A valuable sources of information for not only beginner in area of genome engineering area, but also researchers, students, scientists, clinicians, stakeholders, policy makers and practitioners and many more

Table of Contents

  • 1. An introduction to CRISPR-Cas systems for reprogramming of the genome of mammalian cells
    Vijai Singh
    2. CRISPR-Cas systems for genome editing of mammalian cells
    Indra Mani, Takayuki Arazoe and Vijai Singh
    3. Genome-wide detection and analysis of CRISPR-Cas off-targets
    Tomás C. Rodríguez, Sina Dadafarin, Henry E. Pratt, PengPeng Liu, Nadia Amrani and Lihua Julie Zhu
    4. CRISPR-based diagnostics for detection of pathogens
    Gargi Bhattacharjee, Nisarg Gohil, Navya Lavina Lam and Vijai Singh
    5. Creating cell lines for mimicking diseases
    Edina Poletto and Guilherme Baldo
    6. Modulating Cas9 activity for precision gene editing
    Merve Uslu, Pınar Siyah, Andrew John Harvey and Fatih Kocabas
    7. Crispr-Cas9 in cancer therapeutics
    Shubhchintan Randhawa
    8. CRISPR-Cas9 for treating heredity diseases
    Indra Mani
    9. CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals
    Janardhan Keshav Karapurkar, Ainsley Mike Antao, Kye-Seong Kim and Suresh Ramakrishna
    10. Recent advances in stem cells & gene editing: Drug discovery and therapeutics
    Delger Bayarsaikhan, Govigerel Bayarsaikhan and Bonghee Lee
    11. Genome editing of hPSCs: Recent progress in hPSC-based disease modeling for understanding disease mechanisms
    Dong-Kyu Choi, Yong-Kyu Kim, Ji HoonYu, Sang‑Hyun Min and Sang-Wook Park
    12. Genome editing in cardiovascular diseases
    Indra Mani
    13. CRISPR/Cas9 in epigenetics studies of health and disease
    Pranati Sar and Sarat Dalai
    14. Patents, ethics, biosafety and regulation using CRISPR technology
    Zandile Nxumalo, Mutsa M. Takundwa and Deepak B. Thimiri Govinda Raj

Product details

  • No. of pages: 390
  • Language: English
  • Copyright: © Academic Press 2021
  • Published: June 12, 2021
  • Imprint: Academic Press
  • eBook ISBN: 9780323853248
  • Hardcover ISBN: 9780323853231

About the Serial Volume Editor

Vijai Singh

Dr Vijai Singh is an Associate Professor and Dean (Research & Innovation) at School of Sciences, Indrashil University, Rajpur, Mehsana, Gujarat, India. He was an Assistant Professor in the Department of Biological Sciences and Biotechnology at the Institute of Advanced Research, Gandhinagar, India and also an Assistant Professor in the Department of Biotechnology at the Invertis University, Bareilly, India. Prior to that, he was a Postdoctoral Fellow in the Synthetic Biology Group at the Institute of Systems and Synthetic Biology, Paris, France and School of Energy & Chemical Engineering at the Ulsan National Institute of Science and Technology, Ulsan, South Korea. He received his Ph.D. in Biotechnology (2009) from the National Bureau of Fish Genetic Resources, Uttar Pradesh Technical University, Lucknow, India with a research focus on the development of molecular and immunoassays for diagnosis of Aeromonas hydrophila. His research interests are focused on design of a novel biosynthetic pathways for production of medically and industrially important biomolecules. Additionally, his laboratory focuses on development and implementation of CRISPR-Cas systems for genome editing, regulation and diagnosis. His laboratory is supported by projects from Government of India and industry. He has more than 10 years of research and teaching experience in synthetic biology, metabolic engineering, bioinformatics, microbiology, and industrial microbiology. He has published 79 articles, 51 chapters, 15 books and 4 patents. He serves as an associate editor, editorial board member, and reviewer of several peer-reviewed journals. He is also a member of the Board of Study and Academic Council of Indrashil University and is the Member Secretary of the Institutional Biosafety Committee (IBSC) at the same University.

Affiliations and Expertise

Indrashil University, Gujarat, India

Ratings and Reviews

Write a review

There are currently no reviews for "Reprogramming the Genome: CRISPR-Cas-based Human Disease Therapy"